Answers are grounded in this paper and cite their sources.
Homologous recombination is a high-fidelity DNA repair pathway that preserves genome integrity during replication stress and double-strand break repair. Central to it is the BRCA2–RAD51 axis, in which BRCA2 coordinates RAD51 recruitment, nucleoprotein filament assembly and protection of recombination intermediates. PARP inhibitors have validated synthetic lethality in BRCA-deficient cancers, but their benefit requires pre-existing homologous-recombination deficiency and is limited by acquired resistance. Pharmacological disruption of the BRCA2–RAD51 interface offers a route to a reversible “BRCAness” state in homologous-recombination-proficient tumors. This review examines the structural basis of BRCA2-mediated RAD51 control, the small-molecule disruptors reported to date—triazoles, dihydroquinolone pyrazolines, CAM833, N-acylhydrazones, fragment-derived compounds and quinoline-based analogs—and the peptide, D-amino-acid and aptamer modalities targeting the same axis, together with combination evidence, pancreatic cancer as the dominant disease model, pharmacodynamic biomarkers, selectivity and resistance. Because reported potencies derive from heterogeneous protein constructs and assay formats, the construct used is stated for every value and biochemical and cellular potencies are tabulated separately, and each agent is classified explicitly as a mechanistic probe or an early lead. We emphasize three limitations that the field has not yet addressed: no interface disruptor of any modality has completed in vivo pharmacokinetic–pharmacodynamic characterization, unbound tissue exposure and the reversibility of homologous-recombination inhibition are unmeasured, and peptide and oligonucleotide agents face unresolved barriers of nuclear delivery, proteolytic or nucleolytic degradation, biodistribution and innate immune activation. BRCA2–RAD51 interface disruption is therefore a mechanistically rational but strictly preclinical strategy whose feasibility will be decided by in vivo exposure–response and tolerability data that do not yet exist.
No takes yet. Share an insight, caveat, or question.
Fahad M. Alshabrmi (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: